Aptevo Therapeutics Inc  

(Public, NASDAQ:APVO)   Watch this stock  
Find more results for apvo
0.00 (0.00%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.15 - 4.85
Open     -
Vol / Avg. 0.00/207,753.00
Mkt cap 70.50M
P/E     -
Div/yield     -
EPS -1.82
Shares 21.43M
Beta     -
Inst. own 34%

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 48.35% -308.54%
Operating margin -167.66% -348.42%
EBITD margin - -144.29%
Return on average assets 10.98% -102.37%
Return on average equity 16.89% -161.53%
Employees 118 -
CDP Score - -


2401 4th Ave Ste 1050
SEATTLE, WA 98121-3460
United States - Map
+1-206-8380500 (Phone)
+1-302-6555049 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).